Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of LY4226695 in Healthy Participants
NCT07767487Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Primary completion
- Jul 2027
- Countries
- 2
01
Overview
Phase 1, randomised trial of LY4226695 (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Considered Related to Study Drug. Started Aug 2026; status: recruiting.
02
Drugs
LY4226695
Beyond the preview
Go deeper on NCT07767487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07767487.